benralizumab启动后1年以上的严重嗜酸性哮喘（SEA）患者的早期和持续哮喘控制改善：现实世界的XALOC-2计划

IF 0.3 4区医学

Revue Francaise d Allergologie Pub Date : 2025-03-22 DOI:10.1016/j.reval.2025.104311

A. Didier , L. Dupont , E. Penz , B. Emmanuel , T. Tran , A. Menzies-Gow , A. Shavit , D. Cohen , C. Ho , T. Plate , S. Kayaniyil , A. Herreman , C. Schuoler , M. Lommatzsch , T. Rothe

{"title":"benralizumab启动后1年以上的严重嗜酸性哮喘（SEA）患者的早期和持续哮喘控制改善：现实世界的XALOC-2计划","authors":"A. Didier , L. Dupont , E. Penz , B. Emmanuel , T. Tran , A. Menzies-Gow , A. Shavit , D. Cohen , C. Ho , T. Plate , S. Kayaniyil , A. Herreman , C. Schuoler , M. Lommatzsch , T. Rothe","doi":"10.1016/j.reval.2025.104311","DOIUrl":null,"url":null,"abstract":"<div><h3>Prérequis/contexte</h3><div>Benralizumab depletes blood eosinophils in <24hrs and may lead to rapid improvements in patients (pts) with SEA.</div></div><div><h3>Objectifs</h3><div>To understand the real-world effectiveness of benralizumab on asthma symptom control from 1 to 56 weeks (Wk) post initiation.</div></div><div><h3>Méthodes</h3><div>XALOC-2 comprises prospective, real-world studies (Belgium, Canada, Germany and Switzerland) of benralizumab in pts with SEA. This 56 Wk integrated analysis assessed longitudinal changes in ACQ score.</div></div><div><h3>Résultats/discussions</h3><div>Of 535 pts (median age: 58 yrs; 49% female) mean (SD) ACQ score at baseline (BL) was 3.0 (1.2) decreasing to 1.5 (1.2) by Wk 56. The greatest improvement in ACQ score occurred between BL and Wk 1 and further improved up to Wk 56. Clinically meaningful improvements (minimal clinically-important difference [MCID] threshold=−0.5) were seen in 58% of pts (282/486) at Wk 1. At Wk 56, 79% (276/351) had an improvement ≥1xMCID, and 62% (218/351) ≥2xMCID. Significantly improved asthma control was seen across all clinically relevant BL characteristic subgroups.</div></div><div><h3>Conclusion</h3><div>Clinically meaningful improvements in asthma symptom control began from 1 Wk post benralizumab initiation or earlier and further improved over 1 yr. Benefits were seen in the overall population and were consistent across key subgroups important to therapeutic decision-making in daily practice.</div></div>","PeriodicalId":49130,"journal":{"name":"Revue Francaise d Allergologie","volume":"65 ","pages":"Article 104311"},"PeriodicalIF":0.3000,"publicationDate":"2025-03-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Early and continued asthma control improvement in patients with severe eosinophilic asthma (SEA) over 1 year post benralizumab initiation: real-world XALOC-2 programme\",\"authors\":\"A. Didier , L. Dupont , E. Penz , B. Emmanuel , T. Tran , A. Menzies-Gow , A. Shavit , D. Cohen , C. Ho , T. Plate , S. Kayaniyil , A. Herreman , C. Schuoler , M. Lommatzsch , T. Rothe\",\"doi\":\"10.1016/j.reval.2025.104311\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Prérequis/contexte</h3><div>Benralizumab depletes blood eosinophils in <24hrs and may lead to rapid improvements in patients (pts) with SEA.</div></div><div><h3>Objectifs</h3><div>To understand the real-world effectiveness of benralizumab on asthma symptom control from 1 to 56 weeks (Wk) post initiation.</div></div><div><h3>Méthodes</h3><div>XALOC-2 comprises prospective, real-world studies (Belgium, Canada, Germany and Switzerland) of benralizumab in pts with SEA. This 56 Wk integrated analysis assessed longitudinal changes in ACQ score.</div></div><div><h3>Résultats/discussions</h3><div>Of 535 pts (median age: 58 yrs; 49% female) mean (SD) ACQ score at baseline (BL) was 3.0 (1.2) decreasing to 1.5 (1.2) by Wk 56. The greatest improvement in ACQ score occurred between BL and Wk 1 and further improved up to Wk 56. Clinically meaningful improvements (minimal clinically-important difference [MCID] threshold=−0.5) were seen in 58% of pts (282/486) at Wk 1. At Wk 56, 79% (276/351) had an improvement ≥1xMCID, and 62% (218/351) ≥2xMCID. Significantly improved asthma control was seen across all clinically relevant BL characteristic subgroups.</div></div><div><h3>Conclusion</h3><div>Clinically meaningful improvements in asthma symptom control began from 1 Wk post benralizumab initiation or earlier and further improved over 1 yr. Benefits were seen in the overall population and were consistent across key subgroups important to therapeutic decision-making in daily practice.</div></div>\",\"PeriodicalId\":49130,\"journal\":{\"name\":\"Revue Francaise d Allergologie\",\"volume\":\"65 \",\"pages\":\"Article 104311\"},\"PeriodicalIF\":0.3000,\"publicationDate\":\"2025-03-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Revue Francaise d Allergologie\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1877032025000831\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revue Francaise d Allergologie","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1877032025000831","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

benralizumab可在24小时内消耗血液嗜酸性粒细胞，并可能导致SEA患者（pts）的快速改善。目的了解benralizumab在开始治疗后1 - 56周（Wk）哮喘症状控制方面的实际有效性。msamthodesxaloc -2包括benralizumab治疗SEA患者的前瞻性、现实世界研究（比利时、加拿大、德国和瑞士）。这项56周的综合分析评估了ACQ评分的纵向变化。535例(中位年龄：58岁；49%女性)基线时ACQ评分（BL）平均（SD）为3.0(1.2)，到第56周时降至1.5（1.2）。ACQ评分的最大改善发生在BL和第1周之间，并进一步改善到第56周。在第1周，58%的患者（282/486）有临床意义的改善（最小临床重要差异[MCID]阈值= - 0.5）。在第56周，79%（276/351）患者的改善≥1xmedd， 62%（218/351）患者的改善≥2xmedd。在所有临床相关的BL特征亚组中，哮喘控制均有显著改善。结论：哮喘症状控制的临床意义改善始于贝纳利珠单抗启动后1周或更早，并在1年内进一步改善。在总体人群中观察到益处，并且在日常实践中对治疗决策重要的关键亚组中保持一致。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Early and continued asthma control improvement in patients with severe eosinophilic asthma (SEA) over 1 year post benralizumab initiation: real-world XALOC-2 programme

Prérequis/contexte

Benralizumab depletes blood eosinophils in <24 hrs and may lead to rapid improvements in patients (pts) with SEA.

Objectifs

To understand the real-world effectiveness of benralizumab on asthma symptom control from 1 to 56 weeks (Wk) post initiation.

Méthodes

XALOC-2 comprises prospective, real-world studies (Belgium, Canada, Germany and Switzerland) of benralizumab in pts with SEA. This 56 Wk integrated analysis assessed longitudinal changes in ACQ score.

Résultats/discussions

Of 535 pts (median age: 58 yrs; 49% female) mean (SD) ACQ score at baseline (BL) was 3.0 (1.2) decreasing to 1.5 (1.2) by Wk 56. The greatest improvement in ACQ score occurred between BL and Wk 1 and further improved up to Wk 56. Clinically meaningful improvements (minimal clinically-important difference [MCID] threshold = −0.5) were seen in 58% of pts (282/486) at Wk 1. At Wk 56, 79% (276/351) had an improvement ≥1xMCID, and 62% (218/351) ≥2xMCID. Significantly improved asthma control was seen across all clinically relevant BL characteristic subgroups.

Conclusion

Clinically meaningful improvements in asthma symptom control began from 1 Wk post benralizumab initiation or earlier and further improved over 1 yr. Benefits were seen in the overall population and were consistent across key subgroups important to therapeutic decision-making in daily practice.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Revue Francaise d Allergologie Medicine-Immunology and Allergy

自引率

33.30%

发文量

349

期刊介绍： La Revue Française d''Allergologie : un véritable forum pour faire connaître des travaux originaux et permettre la diffusion de l''information auprès de toutes les spécialités concernées par les pathologies allergiques. La Revue Française d''Allergologie (8 numéros par an) est au carrefour de nombreuses spécialités - dermatologie, pédiatrie, ORL, pneumologie, ophtalmologie, médecine interne - qui, toutes, ont à traiter des maladies allergiques. Les symptômes des allergies fondés sur des mécanismes communs sont le plus souvent associés et se succèdent chez un même patient. En forte progression depuis 20 ans, les maladies allergiques sont dans l''attente de perfectionnements et d''avancées thérapeutiques qui permettront aux nombreux patients qui en sont atteints de mieux vivre avec leurs allergies. La Revue Française d''Allergologie se veut donc un véritable forum de discussions et d''échanges entre tous les spécialistes confrontés aux pathologies